LY3177833 is an CDC7 and pMCM2 inhibitor extracted from patent US 20140275131and patent WO 2014143601 A1 compound example 4; has IC50 values of 3.3 nM and 290 nM, respectively.
CAS：1627696-51-8
分子式：C16H12FN5O
分子量：309.3
纯度：98%
存储：Store at -20°C

Background:

LY3177833 is a CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively[1].

LY3177833 (Compound example 4; 10.4-31.2 mg/kg; oral gavage; twice a day; for 2 weeks; female athymic Balb/c nude mice with SW620 cells) treatment causes significant tumor regression in a dosedependent manner. Also, no significant tumor growth is observed for 2 weeks after dosing cessation[1].

参考文献:
[1]. DALLY, Robert Dean, et al. CDC7 Inhibitors. 18 September 2014. WO2014143601A1.